A double-blind study in hypertensive patients of an original new compound, indapamide.
In a double-bind crossover study in 18 patients with essential hypertension, the hypotensive activity of 5 mg. indapamide daily was compared with 40 mg. frusemide daily over a period of 4 months after an initial 15 days on placebo. The overall clinical assessment showed satisfactory blood pressure control in 72% of patients receiving indapamide compared with 57% on frusemide. The weight of patients on active therapy dropped significantly with both products, but to a greater extent with indapamide. Indapamide was well-tolerated by all 18 patients; 3 patients on frusemide developed side-effects. The results of blood chemistry investigations are discussed. Variations in potassium levels during indapamide therapy were modest and did not warrant the use of potassium supplements.
D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects; D001549:Benzamides / Q000627:therapeutic use; D001795:Blood Pressure Determination; D001798:Blood Proteins / Q000032:analysis; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004361:Drug Tolerance; D004573:Electrolytes / Q000097:blood; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood
D000959:Antihypertensive Agents; D001549:Benzamides; D001798:Blood Proteins; D004232:Diuretics; D004573:Electrolytes; D007211:Indoles; D014527:Uric Acid; D005665:Furosemide